Trial Profile

A Randomized, Double-Blind, Phase 2 Trial of Once-Weekly Petrelintide Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Petrelintide (Primary)
Indications Obesity; Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms ZUPREME-2
Sponsors Zealand Pharma

Most Recent Events

15 Jan 2026 Planned primary completion date changed from 2 Apr 2026 to 13 Aug 2026.
13 Nov 2025 According to a Zealand Pharma media release, enrollment of all trial participants has been completed in November 2025 and company expects to report topline results from the Phase 2 ZUPREME-2 trial in second half of 2026.
13 Nov 2025 Status changed from recruiting to active, no longer recruiting, according to a Zealand Pharma media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com